Tarsus Pharmaceuticals, Inc. (TARS) investor relations documents from the company's IR site: 8 presentations, 30 press releases; latest deck 2026-08-18. Read in-app with summaries. First-party data.
Tarsus Corporate Presentation — Tarsus Pharmaceuticals' August 2026 investor document highlights XDEMVY's strong growth in Demodex blepharitis, projecting over $2B in peak US sales, and outlines a robust pipeline with multiple potential FDA approvals by 2031.
TARS overview · TARS earnings · TARS financials · TARS KPIs · TARS ownership · TARS peers · TARS filings
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.